Systemic Inflammation Score Using Pretherapeutic Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy DOI Creative Commons

Tianqing Wu,

Zhikai Zheng,

Jiongliang Wang

et al.

Journal of Hepatocellular Carcinoma, Journal Year: 2023, Volume and Issue: Volume 10, P. 2133 - 2145

Published: Nov. 30, 2023

To assess the clinical value of pretherapeutic systemic inflammation score (SIS) in predicting prognosis hepatocellular carcinoma (HCC) after hepatic arterial infusion chemotherapy (HAIC).From February 2016 to April 2021, 415 advanced HCC patients who underwent HAIC at Sun Yat-sen University Cancer Center were randomly divided into training (n = 277) and validation cohorts 138) analyzed. The aspartate aminotransferase-alanine aminotransferase ratio (AAR), lymphocyte × albumin (L A), neutrophil monocyte (N M) used construct SIS based on a multivariate Cox analysis cohort. A nomogram consisting was created evaluated by calibration plot, areas under receiver operating characteristic (AUC) curve, decision curve (DCA).Univariate analyses revealed that an independent predictor OS. high associated with large tumor size (P < 0.05), multiple lesions 0.01), AFP level extrahepatic metastasis BCLC stage 0.01). Kaplan-Meier showed had shorter OS than those low both non-PD (p 0.015) PD group 0.023). plots good concordance between nomogram's prediction actual observations cohorts. In cohort, AUCs 2-year 3-year survival rates 0.749 0.739, respectively; they 0.760 0.681, respectively. Based AUC DCA, better predictive ability other predictors.The is potential prognostic for undergoing HAIC.

Language: Английский

Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives DOI Creative Commons
Jianzhong Liu, Shuai Xia, Baoyi Zhang

et al.

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: July 3, 2024

Abstract Liver cancer is the sixth most commonly diagnosed and third leading cause of death in world, hepatocellular carcinoma (HCC) common form liver cancer. More than half HCC patients are at an advanced stage often require systemic therapy. Dysregulation activity receptor tyrosine kinases (RTKs) involved development progress HCC, RTKs therefore potential targets for therapy (aHCC). Currently, a total six small molecule kinase inhibitors (TKIs) have been approved aHCC, including first-line sorafenib, lenvatinib, donafenib, second-line regorafenib, cabozantinib, apatinib. These TKIs improved survival, which associated with disease stage, etiology, function, tumor burden, baseline levels alpha-fetoprotein, treatment history. This review focuses on clinical outcomes these key trials, retrospective real-world studies discusses future perspectives aim to provide up-to-date evidence decision-making aHCC.

Language: Английский

Citations

2
Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma DOI Creative Commons
Teng Long,

Zhoutian Yang,

Huilan Zeng

et al.

Journal of Hepatocellular Carcinoma, Journal Year: 2023, Volume and Issue: Volume 10, P. 1849 - 1859

Published: Oct. 1, 2023

To compare the treatment efficacy and safety of transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) combined with tyrosine kinase inhibitors (TKIs) programmed cell death protein-1 (PD-1) for patients unresectable hepatocellular carcinoma (HCC).81 HCC were retrospectively analyzed, including 30 51 treated either TKIs PD-1 TACE (TTP) HAIC (HTP), respectively. Tumor response survival outcomes compared.The median overall (mOS) was 21.0 months in TTP group 15.0 HTP (P = 0.525; HR 1.23; 95% CI 0.66-2.29). The progression-free (mPFS) 6.7 9.9 0.160; 0.70; 0.42-1.16). After Propensity Score Matching (PSM), mOS 18.0 0.644; 1.20; 0.56-2.58). mPFS 6.4 0.028; 0.49; 0.26-0.93). disease control rate (90.2% vs 76.7%, P 0.116, before PSM; 91.7% 75.0%, 0.121, after PSM) intrahepatic (94.1% 80.0%, 0.070, 79.2%, 0.220, higher than group.Though more advanced tumors, clinical are comparable to TACE-based combination therapy HCC. Nevertheless, significantly improved PFS benefits large tumor burden vascular invasion.

Language: Английский

Citations

4
Sorafenib plus memory-like natural killer cell immunochemotherapy boosts treatment response in liver cancer DOI Creative Commons
Aydιn Eresen,

Zigeng Zhang,

Guangbo Yu

et al.

BMC Cancer, Journal Year: 2024, Volume and Issue: 24(1)

Published: Sept. 30, 2024

Language: Английский

Citations

1
Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma DOI Creative Commons

Jianwu Long,

Longfei Liu, Xuefeng Yang

et al.

Pakistan Journal of Medical Sciences, Journal Year: 2023, Volume and Issue: 39(6)

Published: Sept. 11, 2023

Objectives: To investigate the impact of combining lenvatinib with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC). Methods: This was a retrospective observational study which reviewed medical records 103 HCC patients from January 2017 to June 2020 in The First Affiliated Hospital Soochow University. It included 46 who received TACE plus and 57 alone. levels serum indicators, clinical effect, adverse events, overall survival (OS), progression-free (PFS) were compared between two groups. Results: AFP VEGF TACE+lenvatinib group post-treatment significantly lower than (P<0.05). efficacy (69.57%) higher that (40.35%) There significant differences hypertension, diarrhea, bleeding (gingiva) groups no one or year PFS rate OS (P>0.05), while years (P<0.05). Conclusions: combined have high effective rate, reduced levels, acceptable incidence events. doi: https://doi.org/10.12669/pjms.39.6.7944 How cite this: Long J, Liu L, Yang X, Lu Qin L. Impact Lenvatinib Transarterial carcinoma. Pak J Med Sci. 2023;39(6):---------. is an Open Access article distributed under terms Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), permits unrestricted use, distribution, reproduction any medium, provided original work properly cited.

Language: Английский

Citations

2
Hepatocellular carcinoma: Advances in systemic therapies DOI Creative Commons

Trevor Kwan-Hung Wu,

Rex Wan‐Hin Hui, Lung‐Yi Mak

et al.

F1000Research, Journal Year: 2024, Volume and Issue: 13, P. 104 - 104

Published: Feb. 16, 2024

Advanced hepatocellular carcinoma (HCC) is traditionally associated with limited treatment options and a poor prognosis. Sorafenib, multiple tyrosine kinase inhibitor, was introduced in 2007 as first-in-class systemic agent for advanced HCC. After sorafenib, range of targeted therapies immunotherapies have demonstrated survival benefits the past 5 years, revolutionizing landscape More recently, evidence novel combinations agents distinct mechanisms has emerged. In particular, combination trials on atezolizumab plus bevacizumab durvalumab tremelimumab shown encouraging efficacy. Hence, international societies revamped their guidelines to incorporate new recommendations these agents. Aside from HCC, indications therapy are expanding. For example, therapeutics locoregional (trans-arterial chemoembolization or stereotactic body radiation therapy) promising early results downstaging Recent also explored role neoadjuvant borderline-resectable HCC adjuvant reduce recurrence risk after curative resection. Despite clinical trials, real-world efficacy specific patient subgroups (such patients cirrhosis, high bleeding risk, renal impairment, cardiometabolic diseases) remains uncertain. The effect liver disease etiology warrants further research. With an increased understanding pathophysiological pathways accumulation data, personalized decisions will be possible, field continue evolve.

Language: Английский

Citations

0
MRI monitoring of combined therapy with transcatheter arterial delivery of NK cells and systemic administration of sorafenib for the treatment of HCC DOI Open Access

Zigeng Zhang

American Journal of Cancer Research, Journal Year: 2024, Volume and Issue: 14(5), P. 2216 - 2227

Published: Jan. 1, 2024

This preclinical study explored the synergistic potential of sorafenib and NK cell chemoimmunotherapy to combat hepatocellular carcinoma (HCC) in a rat model. We aimed enhance cytotoxicity through IL-12/18 cytokines supplementation elucidate underlying molecular mechanisms driving this collaborative antitumor action. Twenty-four Sprague-Dawley rats were divided into distinct treatment groups, receiving via gavage cells catheterization proper hepatic artery. Tumor growth response monitored weekly MRI scans, including T1w, T2w, DCE, DWI sequences. Histological examinations assessed tumor viability, apoptosis fraction, microvessel density. The combined therapy demonstrated significant inhibition growth, angiogenesis, induction durable immunity compared either modality alone. DCE-MRI revealed alterations microvasculature, highlighting effectiveness combination. Our findings highlight promise sorafenib-augmented as therapeutic strategy for HCC management. targeted delivery supplemented effectively enhanced within microenvironment, leading improved responses. Further investigation clinical trials is warranted validate these human patients explore translational approach.

Language: Английский

Citations

0
Comprehensive Management of Hepatocellular Carcinoma: A Review of Current Surgical, Locoregional, and Systemic Therapies DOI Open Access

Omnia Ahmed,

Rehab H. Werida, Safaa Askar

et al.

Deleted Journal, Journal Year: 2024, Volume and Issue: 0(0), P. 0 - 0

Published: Aug. 19, 2024

The most frequent primary liver cancer is called hepatocellular carcinoma (HCC), which presents serious clinical difficulties because of its aggressiveness and frequently late-stage diagnosis. A significant health burden in Egypt associated with hepatitis C virus (HCV) infection, highly prevalent. Liver resection transplantation are two possibilities for curative treatment; each has advantages disadvantages own. For tiny tumors, local ablative therapies including cryoablation, microwave ablation, radiofrequency ablation (RFA) work well. Systemic sorafenib, lenvatinib, immunotherapy essential advanced stages HCC, while locoregional therapies, such as transarterial chemoembolization (TACE) radioembolization (TARE), target intermediate-stage HCC. Novel approaches, like gene therapy combination medicines, demonstrate the continuous progress HCC treatment. In order to improve patient outcomes, effective requires a multidisciplinary strategy that includes supportive palliative care. Improving prognosis early discovery using diagnostic imaging biomarkers, well screening programs. maximize management care, it crucial comprehend intricate interactions between staging systems, prognostic variables, therapeutic modalities.

Language: Английский

Citations

0
A patient-derived HCC spheroid system to model the tumor microenvironment and treatment response DOI Creative Commons

Émilie Crouchet,

Nuno Almeida,

Sarah Durand

et al.

JHEP Reports, Journal Year: 2024, Volume and Issue: 7(2), P. 101252 - 101252

Published: Oct. 28, 2024

Language: Английский

Citations

0
The ncRNA-AURKA Interaction in Hepatocellular Carcinoma: Insights into Oncogenic Pathways, Therapeutic Opportunities, and Future Challenges DOI Creative Commons

Clarissa Joy C. Garcia,

Luca Grisetti, Claudio Tiribelli

et al.

Life, Journal Year: 2024, Volume and Issue: 14(11), P. 1430 - 1430

Published: Nov. 6, 2024

Hepatocellular carcinoma (HCC) represents a major public health concern and ranks among the leading cancer-related mortalities globally. Due to frequent late-stage diagnosis of HCC, therapeutic options remain limited. Emerging evidence highlights critical role non-coding RNAs (ncRNAs) in regulation Aurora kinase A (AURKA), one key hub genes involved several cancer pathways. Indeed, dysregulated interaction between ncRNAs AURKA contributes tumor development, progression, resistance. This review delves into interplay their hepatocarcinogenesis. Recent findings underscore involvement axis development progression. Furthermore, this also discusses clinical significance targeting ncRNA-AURKA axes, offering new perspectives that could lead innovative strategies aimed at improving outcomes for HCC patients.

Language: Английский

Citations

0
Downstaging Hepatocellular Carcinoma before Transplantation DOI
Jessica Lindemann, Jennifer Yu,

Maria B. Majella Doyle

et al.

Surgical Oncology Clinics of North America, Journal Year: 2023, Volume and Issue: 33(1), P. 143 - 158

Published: Sept. 16, 2023

Language: Английский

Citations

1